For over four decades, Jinji Capsules—a traditional Chinese medicine (TCM) formulation rooted in Zhuang ethnic medicinal knowledge—has served as a trusted therapeutic option for women managing common gynecological inflammatory conditions. Originally developed from a time-honored folk remedy in Guangxi Province, the formula combines key botanicals including Rhizoma Smilacis Glabrae (Jinyinggen), Caulis Spatholobi (Jixueteng), and Radix Millettiae Speciosae (Qianjinba), which collectively address lower abdominal pain, leukorrhea, and associated discomfort. Additional components such as Radix Zanthoxyli (Liangmianzhen), Herba Andrographis (Chuanxinlian), and Wood of Ardisia crispa (Gonglaomu) contribute antimicrobial and analgesic properties, supporting clinical management of salpingitis, endometritis, and pelvic inflammatory disease—particularly when presenting with lumbosacral soreness, cold sensation in the lower abdomen, increased or malodorous vaginal discharge, and persistent pelvic pain.
First commercialized in 1985 by the Affiliated Pharmaceutical Factory of Guangxi Institute of Traditional Chinese Medicine (the predecessor of Lingfeng Pharmaceutical), the herbal decoction was reformulated into a standardized capsule dosage form—marking the beginning of its modern clinical application. Its consistent efficacy and quality control earned it national recognition: it received the China National Quality Award Silver Prize twice (in 1985 and 1990), was designated a State-Protected Traditional Chinese Medicine (Grade II) in 1995, included in the National Essential Medicines List in 1998, granted a seven-year extension of protection in 2002, and named a Guangxi Famous Product in 2005.
In the early 2000s, U.S.-based Oriental Biotechnology Co., Ltd. (AOBO) acquired Lingfeng Pharmaceutical, facilitating Jinji Capsules’ international expansion across Southeast Asia—including Vietnam, Thailand, Malaysia, and Singapore—where it gained prominence as a recognizable brand in women’s reproductive health care. In 2016, Bangqi Pharmaceutical Group assumed full operational control, initiating a comprehensive revitalization strategy grounded in scientific rigor, regulatory compliance, and patient-centered care.
Under Bangqi’s stewardship, the product underwent strategic modernization: packaging and visual identity were redesigned to reflect contemporary standards for gynecologic therapeutics; Good Agricultural Practice (GAP)-certified cultivation bases were established to ensure traceability and potency of raw herbs; and an integrated quality management system spanning cultivation, extraction, manufacturing, and stability testing was implemented to uphold batch-to-batch consistency and safety.
Recognizing the importance of evidence-informed practice, Bangqi launched the “Jinji Women’s Health Initiative” in 2020—delivering continuing medical education for primary-care clinicians and community-based health literacy programs for patients. This initiative supports shared decision-making and reinforces appropriate indications for Jinji Capsules within integrative gynecologic care pathways.
In 2023, Bangqi introduced the brand positioning “Gentle Regulation, Sustained Wellness,” emphasizing the formulation’s role not only in symptom relief but also in restoring physiological balance—a concept aligned with TCM principles of harmonizing Qi and Blood and strengthening the Ren and Chong meridians. The messaging underscores the dual therapeutic approach of treatment and functional support, distinguishing Jinji Capsules among conventional anti-inflammatory agents.
Building on this foundation, Bangqi executed a multi-platform marketing campaign in 2024—including national television programming such as CCTV’s National Health Medicines series and provincial satellite network broadcasts—as well as targeted digital outreach via B2B professional portals and direct-to-consumer health platforms. These efforts aim to broaden clinical awareness while maintaining fidelity to pharmacovigilance standards and regulatory requirements for herbal medicines in China and abroad.
From its origins in Zhuang ethnobotanical tradition to its current status as a nationally recognized, internationally distributed gynecologic TCM, Jinji Capsules exemplifies how heritage formulations can evolve through rigorous science, ethical stewardship, and responsive public health engagement. As Bangqi Pharmaceutical continues to advance quality infrastructure, clinician education, and patient empowerment initiatives, Jinji Capsules remains committed to its enduring mission: supporting women’s reproductive health through gentle, evidence-informed, and culturally grounded care.